Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 7—July 2010

CME ACTIVITY - Perspective

Extensive Drug Resistance in Malaria and Tuberculosis

CME Logo

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at; (4) view/print certificate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Define multidrug-resistant tuberculosis and describe effective management strategies.

  • Identify multidrug-resistant malaria and discuss management issues.


P. Lynne Stockton, VMD, MS, copy editor, Emerging Infectious Diseases. Disclosure: P. Lynne Stockton, VMD, MS, has disclosed no relevant financial relationships.


Charles P. Vega, MD, Associate Professor; Residency Director, Department of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed no relevant financial relationships.


Disclosures: Chansuda Wongsrichanalai, MD, DrPH; Jay K. Varma, MD; Jonathan J. Juliano, MD, MSPH; and John R. MacArthur, MD, MPH, have disclosed no relevant financial relationships. Michael E. Kimerling, MD, MPH, has disclosed that he owns stock in Amgen, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Merck & Co., Inc.; and Novartis Pharmaceuticals Corporation..


Article Navigation